The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis
Abstract
Long-term treatment with glucagon-like peptide (GLP)-1 or its analog can improve insulin sensitivity. However, continuous administration is required due to its short half-life. We hypothesized that continuous production of therapeutic levels of GLP-1 in vivo by a gene therapy strategy may remit hyperglycemia and maintain prolonged normoglycemia. We produced a recombinant adenovirus expressing GLP-1 (rAd-GLP-1) under the cytomegalovirus promoter, intravenously injected it into diabetic ob/ob mice, and investigated the effect of this treatment on remission of diabetes, as well as the mechanisms involved. rAd-GLP-1–treated diabetic ob/ob mice became normoglycemic 4 days after treatment, remained normoglycemic over 60 days, and had reduced body weight gain. Glucose tolerance tests found that exogenous glucose was cleared normally. rAd-GLP-1–treated diabetic ob/ob mice showed improved β-cell function, evidenced by glucose-responsive insulin release, and increased insulin sensitivity, evidenced by improved insulin tolerance and increased insulin-stimulated glucose uptake in adipocytes. rAd-GLP-1 treatment increased basal levels of insulin receptor substrate (IRS)-1 in the liver and activation of IRS-1 and protein kinase C by insulin in liver and muscle; increased Akt activation was only observed in muscle. rAd-GLP-1 treatment reduced hepatic glucose production and hepatic expression of phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, and fatty acid synthase in ob/ob mice. Taken together, these results show that a single administration of rAd-GLP-1 results in the long-term remission of diabetes in ob/ob mice by improving insulin sensitivity through restoration of insulin signaling and reducing hepatic gluconeogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its main roles are the stimulation of insulin release [30], suppression of glucagon secretion [31], delay of gastric emptying and reduction in food intake [32].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [32]
In the citing paper
“Metabolic effects mediated by GLP-1 include increased glucose uptake and glycogen production in skeletal muscle, as well as inhibition of gluconeogenesis in the liver [38]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [38]
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 3×
“In type 2 diabetic patients, subcutaneous infusion of GLP-1 for 6 weeks resulted in improved insulin sensitivity and -cell function (6).”
BackgroundResultKohn, A. D., Summers, S. A., Birnbaum, M. J., & Roth, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31372 · Cited by 1,284
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling
SHEPHERD, P. R., WITHERS, D. J., & SIDDLE, K. (1998) · Biochemical Journal · doi:10.1042/bj3330471 · Cited by 953
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757 · cited 1×
“Elevated hepatic glucose production, due to increased gluconeogenesis, glycogenolysis, or both, is associated with the pathogenesis of type 2 diabetes (38,39).”
BackgroundREGULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE EXPRESSION
Hanson, R. W., & Reshef, L. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.581 · Cited by 729 · cited 1×
“The expression of G6Pase, which is involved in gluconeogenesis and glycogenolysis (40), and PEPCK, which is involved in gluconeogenesis (41), was significantly decreased in the liver of rAd-GLP-1–treated ob/ob mice, suggesting that the blood glucose–lowering effect of rAdGLP-1 might be due in part to the reduction of…”
BackgroundProtein Kinase B/Akt Participates in GLUT4 Translocation by Insulin in L6 Myoblasts
Wang, Q., Somwar, R., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R., & Klip, A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4008 · Cited by 592
REGULATION OF GLUCOSE PRODUCTION BY THE LIVER
Nordlie, R. C., Foster, J. D., & Lange, A. J. (1999) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.19.1.379 · Cited by 585
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 5×
“Similarly, treatment with exendin-4 or GLP-1 reduced fasting serum insulin levels in ob/ob and db/db mice (4,21).”
BackgroundMethodResultInfluentialDegn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · cited 1×
“This result is consistent with previous findings, which showed that continuous infusion of GLP-1 or treatment with GLP-1 analog had no effect on fasting glucagon levels (6,43,44).”
ResultEssential Role for Protein Kinase B (PKB) in Insulin-induced Glycogen Synthase Kinase 3 Inactivation
van Weeren, P. C., de Bruyn, K. M. T., de Vries-Smits, A. M. M., van Lint, J., & Burgering, B. M. T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13150 · Cited by 365
Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., Landau, B. R., & Ferrannini, E. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1367 · Cited by 320
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Wang, Q., & Brubaker, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0828-3 · Cited by 312
Isoform-specific Regulation of Insulin-dependent Glucose Uptake by Akt/Protein Kinase B
Bae, S. S., Cho, H., Mu, J., & Birnbaum, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306782200 · Cited by 311
Activation of Protein Kinase C (α, β, and ζ) by Insulin in 3T3/L1 Cells
Bandyopadhyay, G., Standaert, M. L., Zhao, L., Yu, B., Avignon, A., Galloway, L., Karnam, P., Moscat, J., & Farese, R. V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2551 · Cited by 288
The Role of Macrophages in T Cell–mediated Autoimmune Diabetes in Nonobese Diabetic Mice
Jun, H.-S., Yoon, C.-S., Zbytnuik, L., van Rooijen, N., & Yoon, J.-W. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.347 · Cited by 279
Self-citationOlefsky, J. M. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108231 · Cited by 277
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271
Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A. D., Parkes, D. G., & Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 242
Farese, R. V., Sajan, M. P., & Standaert, M. L. (2005) · Experimental Biology and Medicine · doi:10.1177/153537020523000901 · Cited by 185
Mayo Johnson, M. E., Das, N. M., Butcher, F. R., & Fain, J. N. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)45235-6 · Cited by 180
Insulin resistance in noninsulin-dependent diabetes mellitus
Reaven, G. M. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90650-2 · Cited by 154 · cited 1×
“Impaired glucose transport is one of the major factors contributing to insulin resistance, and insulin-mediated glucose disposal is greatly reduced in type 2 diabetes (24).”
BackgroundGlucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu, H., Wiesenthal, S. R., MacDonald, P. E., McCall, R. H., Tchipashvili, V., Rashid, S., Satkunarajah, M., Irwin, D. M., Shi, Z. Q., BRUBAKER, P. L., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1045 · Cited by 132
Signalling through the insulin receptor
Whitehead, J. P., Clark, S. F., Ursø, B., & James, D. E. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00079-4 · Cited by 130
Insulin Regulation of Fatty Acid Synthase Gene Transcription: Roles of USF and SREBP‐1c
Griffin, M. J., & Sul, H. S. (2004) · IUBMB Life · doi:10.1080/15216540400022474 · Cited by 126
GLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 113
Meneilly, G. S., Greig, N. H., Tildesley, H. D., Habener, J. F., Egan, J. M., & Elahi, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2835 · Cited by 103
Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPβ gene
Liu, S., Croniger, C. M., Arizmendi, C., Harada‐Shiba, M., Ren, J., Poli, V., Hanson, R. W., & Friedman, J. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4243 · Cited by 94
Seoane, J., Trinh, K., O'Doherty, R. M., Gómez-Foix, A. M., Lange, A. J., Newgard, C. B., & Guinovart, J. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.26972 · Cited by 82
Standaert, M. L., Sajan, M. P., Miura, A., Kanoh, Y., Chen, H. C., Farese, R. V., & Farese, R. V. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402440200 · Cited by 79
Genetic differences in susceptibility of pancreatic β cells to virus-induced diabetes mellitus
Yoon, J., Lesniak, M. A., Fußgänger, R., & Notkins, A. L. (1976) · Nature · doi:10.1038/264178a0 · Cited by 71
Self-citationKumar, M., Hunag, Y. P., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302836 · Cited by 71
Kim, W. I., Khil, L., Clark, R., Bok, S. H., Kim, E. E., Lee, S., Jun, H., & Yoon, J. (2006) · Diabetologia · doi:10.1007/s00125-006-0373-6 · Cited by 60
Self-citationKendall, D. M., Kim, D. S., & Maggs, D. G. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.385 · Cited by 48
GLP-1 gene delivery for the treatment of type 2 diabetes
Oh, S., Lee, M., Ko, K. S., Choi, S.-A., & Kim, S. W. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00036-4 · Cited by 48
Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes
Parsons, G. B., Souza, D. W., Wu, H., Yu, D., Wadsworth, S. G., Gregory, R. J., & Armentano, D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302842 · Cited by 45
Liu, M.-J., Shin, S., Li, N., Shigihara, T., Lee, Y.-S., Yoon, J., & Jun, H. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300005 · Cited by 44
Self-citationInsulin-Receptor Tyrosine Kinase and Glucose Transport
Lane, M. D., Flores-Riveros, J. R., Hresko, R. C., Kaestner, K. H., Liao, K., Janicot, M., Hoffman, R. D., McLenithan, J. C., Kastelic, T., & Christy, R. J. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.565 · Cited by 41
Fatty Acid Synthesis in Obese Insulin Resistant Diabetic Mice
Memon, R., Grünfeld, C., Moser, A., & Feingold, K. K. (1994) · Hormone and Metabolic Research · doi:10.1055/s-2007-1000778 · Cited by 36
Barnett, A. H. (2005) · Drugs of today · doi:10.1358/dot.2005.41.9.893704 · Cited by 35
Insulin's expanding control of forkheads
Czech, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135308100 · Cited by 32
Radziuk, J., & Pye, S. (2001) · Diabetologia · doi:10.1007/s001250100589 · Cited by 28
Lavau, M. M., Bazin, R., KARAOGHLANIAN, Z., & Guichard, C. (1982) · Biochemical Journal · doi:10.1042/bj2040503 · Cited by 25
GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
Márquez, L., González, N., Puente, J., Valverde, L., & Villanueva‐Peñacarrillo, M. L. (2001) · PubMed · Cited by 8
Cited by
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“…show that injection of a recombinant adenovirus expressing GLP-1 into obese diabetic mice increases insulin-stimulated glucose uptake in adipocytes (Lee et al., 2007), and GLP-1 also augments insulin-stimulated glucose uptake along with an increase in glucose transporter levels in 3T3-L1…”
BackgroundGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Self-citation
Metadata
- Authors
- Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S.
- Affiliations
- Rosalind Franklin University of Medicine and Science (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 56
- Issue
- 6
- Pages
- 1671-1679
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2096880961
- Cited by
- 158
- References
- 50
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 11 · 2019: 10 · 2018: 8 · 2017: 8 · 2016: 10 · 2015: 11 · 2014: 7 · 2013: 7 · 2012: 12
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- glucagon-like peptide-1, gene therapy, adenoviral vector, ob/ob mice, obesity, type 2 diabetes, diabetes remission, insulin sensitivity, hepatic gluconeogenesis, insulin signaling, IRS-1, beta-cell function, glucose tolerance, insulin-stimulated glucose uptake, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, fatty acid synthase
- MeSH terms
- Animals, Diabetes Mellitus, Experimental, Gluconeogenesis, Glucose Tolerance Test, Insulin, Liver, Mice, Obese, RNA, Messenger, Genetic Therapy, Reverse Transcriptase Polymerase Chain Reaction, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.